secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-04-18T23:59:59+00:00
Accession:  0001641172-25-005427
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma receives Nasdaq delisting notices for MVLS below $50M and bid price under $1.00
--------------------------------------------------------------------------------

- Received two letters on April 16, 2025: MVLS deficiency (below $50M for 30 consecutive days) and bid price deficiency (below $1.00).
- Company has 180 days until October 13, 2025 to regain compliance with MVLS; must achieve at least $50M for 10 consecutive business days.
- Bid Price Rule allows 180-day compliance period; failure may lead to delisting or transfer to Nasdaq Capital Market.
- Company is evaluating potential responses but has not decided on actions; no assurance of regaining compliance.
- Tickers affected: ASBP (common stock) and ASBPW (warrants), both on Nasdaq Global Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/0001641172-25-005427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer